|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,566.90 INR | -2.79% |
|
-3.48% | -8.44% |
| 07-02 | US Committee Launches Probe Against Five Drugmakers Over China Clinical Trials | MT |
| 07-01 | US Committee Launches Probe Against Five Drugmakers over China Clinical Trials | MT |
Company Valuation: Pfizer Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 198,918 | 158,614 | 191,909 | 183,197 | 215,952 | 208,925 | - |
| Change | - | -20.26% | 20.99% | -4.54% | 17.88% | -3.25% | - |
| Enterprise Value (EV) | 198,918 | 158,614 | 191,909 | 183,197 | 215,952 | 208,925 | 208,925 |
| Change | - | -20.26% | 20.99% | -4.54% | 17.88% | -3.25% | 0% |
| P/E | 32.5x | 25.4x | 34.8x | 23.9x | 29.9x | 25.1x | 22.5x |
| PBR | 6.94x | 4.95x | 5.34x | 4.34x | 5.14x | 4.4x | 3.88x |
| PEG | - | 13.66x | -3x | 0.6x | -5.08x | 1.7x | 1.9x |
| Capitalization / Revenue | 7.62x | 6.54x | 8.75x | 8.03x | 8.57x | 7.67x | 7.01x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 7.67x | 7.01x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 21.7x | 19.7x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 22x | 19.9x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 40.9x | 31.9x |
| FCF Yield | 4.19% | 1.83% | 1.24% | 3.45% | 4.36% | 2.44% | 3.13% |
| Dividend per Share 2 | 35 | 35 | 35 | 35 | 75 | 69.45 | 71.2 |
| Rate of return | 0.8% | 1.01% | 0.83% | 0.87% | 1.59% | 1.52% | 1.56% |
| EPS 2 | 133.9 | 136.4 | 120.5 | 167.8 | 157.9 | 181.8 | 203.1 |
| Distribution rate | 26.1% | 25.7% | 29% | 20.9% | 47.5% | 38.2% | 35.1% |
| Net sales 1 | 26,110 | 24,248 | 21,932 | 22,814 | 25,196 | 27,241 | 29,818 |
| EBITDA 1 | 8,357 | 8,089 | 6,353 | 7,402 | 9,041 | 9,620 | 10,604 |
| EBIT 1 | 7,207 | 7,034 | 5,730 | 6,794 | 8,464 | 9,512 | 10,512 |
| Net income 1 | 6,126 | 6,239 | 5,513 | 7,676 | 7,224 | 8,315 | 9,292 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 4,348.15 | 3,467.15 | 4,194.95 | 4,004.50 | 4,720.50 | 4,566.90 | 4,566.90 |
| Nbr of stocks (in thousands) | 45,748 | 45,748 | 45,748 | 45,748 | 45,748 | 45,748 | - |
| Announcement Date | 20/05/22 | 15/05/23 | 17/05/24 | 19/05/25 | 12/05/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 25.13x | - | - | 1.52% | 2.17B | ||
| 35.04x | 12.53x | 26.21x | 0.57% | 1,051B | ||
| 27.19x | 6.2x | 16.98x | 2.12% | 609B | ||
| 33.15x | 7.52x | 15.43x | 2.7% | 450B | ||
| 17.85x | 4.43x | 10.91x | 3% | 330B | ||
| 21.66x | 5.55x | 13.44x | 2.84% | 284B | ||
| 21.16x | 4.46x | 12.34x | 1.97% | 263B | ||
| 14.44x | 5.41x | 11.14x | 3.44% | 223B | ||
| 24.02x | 6.35x | 11.22x | 2.75% | 198B | ||
| -48.37x | 5.78x | 31.95x | 2.42% | 167B | ||
| Average | 17.13x | 6.47x | 16.62x | 2.33% | 357.72B | |
| Weighted average by Cap. | 24.01x | 7.82x | 18.33x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PFIZER Stock
- Valuation Pfizer Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















